The approach, called GRAND, uses a second guide RNA to write complementary strands of DNA in targeted genomic locations, resulting in efficient insertions that can be hundreds of base pairs long.
Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?